Search Results - "Ramalingam, S.S"

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients by Remon, J, Steuer, C E, Ramalingam, S S, Felip, E

“…Abstract Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for…”
Get full text

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study by Ramalingam, S.S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B.C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., Todd, A., Markovets, A., Barrett, J.C., Chmielecki, J., Gray, J.

Get full text

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis by Ramalingam, S.S., Gray, J.E., Ohe, Y., Cho, B.C., Vansteenkiste, J., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Lee, K.H., Cheema, P., Tiseo, M., John, T., Lin, M.C., Imamura, F., Hodge, R., Rukazenkov, Y., Soria, J.-C., Planchard, D.

Get full text

Evaluation of Hospitalization Trends in Lung Cancer Patients With Hyponatremia by Kazi, H.A, Behera, M, Steuer, C, Pillai, R.N, Owonikoko, T.K, Khuri, F.R, Ramalingam, S.S

Get full text

A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction by Hall, W.A, Steuer, C.E, Nickleach, D.C, Behera, M, Owonikoko, T.K, Higgins, K.A, Khuri, F.R, Curran, W.J, Ramalingam, S.S

Get full text

A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction by Hall, W.A, Steuer, C.E, Nickleach, D.C, Behera, M, Owonikoko, T.K, Higgins, K.A, Khuri, F.R, Curran, W.J, Ramalingam, S.S

Get full text

3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies by Goss, G.D, Yang, J.C.H, Ahn, M.J, Tsai, C.M, Bazhenova, L, Sequist, L.V, Ramalingam, S.S, Shepherd, F.A, Ghiorghiu, S, Cantarini, M, Mann, H, Mitsudomi, T, Jänne, P.A

Get full text

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) by Gettinger, S.N, Horn, L, Ramalingam, S.S, Spigel, D.R, Paz-Ares, L, Paik, P, Reck, M, Reckamp, K, Mazières, J, Stinchcombe, T, Lynch, M, Brahmer, J

Get full text

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies by Ahn, M.J, Tsai, C.M, Yang, J.C.H, Shepherd, F.A, Satouchi, M, Kim, D.W, Bazhenova, L, Hirashima, T, Rukazenkov, Y, Cantarini, M, Mann, H, Ramalingam, S.S, Mitsudomi, T, Jänne, P.A, Goss, G.D

Get full text

Postoperative Radiation Therapy (PORT) Is Associated With Better Survival in Non-Small Cell Lung Cancer With Involved N2 Lymph Nodes by Mikell, J.L, Gillespie, T.W, Hall, W.A, Nickleach, D.C, Liu, Y, Lipscomb, J, Ramalingam, S.S, Rajpara, R.S, Force, S.D, Fernandez, F.G, Owonikoko, T.K, Pillai, R.N, Khuri, F.R, Jegadeesh, N.K, Curran, W.J, Higgins, K.A

Get full text

Higher Dose of Palliative Thoracic Radiation Is Associated With Improved Survival for Patients With Stage IV Non-Small Cell Lung Cancer by Rajpara, R.S, Gillespie, T.W, Nickleach, D.C, Liu, Y, Lipscomb, J, Fernandez, F.G, Mikell, J.L, Ramalingam, S.S, Owonikoko, T.K, Pillai, R.N, Khuri, F.R, Curran, W.J, Higgins, K.A

Get full text

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer by Ramalingam, S.S, Kotsakis, A, Tarhini, A.A, Heron, D.E, Smith, R, Friedland, D, Petro, D.P, Raez, L.E, Brahmer, J.R, Greenberger, J.S, Dacic, S, Hershberger, P, Landreneau, R.J, Luketich, J.D, Belani, C.P, Argiris, A

“…Abstract Background Cetuximab has demonstrated improved efficacy in combination with chemotherapy and radiotherapy. We evaluated the integration of cetuximab…”
Get full text

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer by Ramalingam, S.S, Mazières, J, Planchard, D, Stinchcombe, T.E, Dy, G.K, Antonia, S.J, Horn, L, Lena, H, Minenza, E, Mennecier, B, Otterson, G.A, Campos, L.T, Gandara, D.R, Levy, B.P, Nair, S.G, Zalcman, G, Wolf, J, Baudelet, C, Lestini, B.J, Rizvi, N.A

Get full text

1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies by Harvey, R.D, Lewis, C.M, Kauh, J.S, Owonikoko, T.K, Akintayo, A, Karol, M, Teofilovici, F, Lufkin, J.M, Khuri, F.R, Ramalingam, S.S

Get full text

A Phase I Study Demonstrating Manganese Superoxide Dismutase Plasmid Liposome Complex (MnSOD-PL) Reduction of Esophagitis following Standard Chemoradiation in Surgically Unresectable Stage III NSCLC by Greenberger, J.S, Belani, C.P, Leuketich, J.D, Argiris, A, Ramalingam, S.S, Gooding, W, Pennathur, A, Petro, D, Epperly, M.W, Tarhini, A.A

Get full text

Sotorasib for Lung Cancers with KRAS p.G12C Mutation by Skoulidis, Ferdinandos, Li, Bob T, Dy, Grace K, Price, Timothy J, Falchook, Gerald S, Wolf, Jürgen, Italiano, Antoine, Schuler, Martin, Borghaei, Hossein, Barlesi, Fabrice, Kato, Terufumi, Curioni-Fontecedro, Alessandra, Sacher, Adrian, Spira, Alexander, Ramalingam, Suresh S, Takahashi, Toshiaki, Besse, Benjamin, Anderson, Abraham, Ang, Agnes, Tran, Qui, Mather, Omar, Henary, Haby, Ngarmchamnanrith, Gataree, Friberg, Gregory, Velcheti, Vamsidhar, Govindan, Ramaswamy

“…Sotorasib is a selective irreversible inhibitor of the G12C-activated KRAS oncogene, present in approximately 13% of non–small-cell lung cancers. In a…”
Get full text

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden by Hellmann, Matthew D, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S, Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J, Geese, William J, Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis

“…Among patients with non–small-cell lung cancer and tumors containing at least 10 mutations per megabase, the 1-year progression-free survival rate was 43% with…”
Get full text

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer by Oxnard, G.R., Yang, J.C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K.S., Frigault, M.M., Vishwanathan, K., Ghiorghiu, D., Ramalingam, S.S., Ahn, M.-J.

“…Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study…”
Get full text

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer by Mok, Tony S, Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C, Kim, Hye R, Ramalingam, Suresh S, Shepherd, Frances A, He, Yong, Akamatsu, Hiroaki, Theelen, Willemijn S.M.E, Lee, Chee K, Sebastian, Martin, Templeton, Alison, Mann, Helen, Marotti, Marcelo, Ghiorghiu, Serban, Papadimitrakopoulou, Vassiliki A

“…In a randomized trial involving patients with non–small-cell lung cancer with mutant EGFR (T790M) in whom a tyrosine kinase inhibitor had failed, osimertinib…”
Get full text

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis by Papadimitrakopoulou, V.A., Mok, T.S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S.S., Kim, S.W., Shepherd, F.A., Laskin, J., He, Y., Akamatsu, H., Theelen, W.S.M.E., Su, W.-C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., Wu, Y.-L.

“…In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged…”
Get full text